Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications

Pouran Layegh; Zeinab Khademi; Monavar Afzal Aghaee; Toktam Moghiman

doi:10.1093/jpids/piu021

Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications

J Pediatric Infect Dis Soc. 2015 Dec;4(4):356-8. doi: 10.1093/jpids/piu021. Epub 2014 Apr 3.

Authors

Pouran Layegh¹, Zeinab Khademi², Monavar Afzal Aghaee³, Toktam Moghiman¹

Affiliations

¹ Cutaneous Leishmaniasis Research Center, Qaem Hospital, School of Medicine.
² Dermatology Department, Qaem Hospital, School of Medicine, Mashhad University of Medical Sciences.
³ Department of Epidemiology and Statistics, Mashhad University of Medical Sciences, Iran.

PMID: 26582874
DOI: 10.1093/jpids/piu021

Abstract

Children account for 7%-20% of cutaneous leishmaniasis cases in Iran, but there are few safety data to guide pediatric antiparasitic therapy. We evaluated the clinical and laboratory tolerance of the systemic pentavalent antimonial compound meglumine antimoniate, in 70 Iranian children with cutaneous leishmaniasis. Adverse effects were similar to those seen in adults.

Keywords: adverse effects; children; cutaneous leishmaniasis; meglumine antimoniate.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antiprotozoal Agents / adverse effects*
Antiprotozoal Agents / therapeutic use
Child
Child, Preschool
Female
Humans
Infant
Iran
Leishmaniasis, Cutaneous / drug therapy*
Male
Meglumine / adverse effects*
Meglumine / therapeutic use
Organometallic Compounds / adverse effects*
Organometallic Compounds / therapeutic use

Substances

Antiprotozoal Agents
Organometallic Compounds
Meglumine